After acute myocardial infarction, prompt restoration of blood flow to the ischemic myocardium - through the use of thrombolytic therapy or primary percutaneous coronary intervention - limits infarct size and reduces mortality. However, the restoration of blood flow can result in additional myocardial damage, a phenomenon referred to as ischemiareperfusion (I-R) injury. Despite many promising preclinical approaches to improve cardiac function after I-R, their clinical translation has thus far yielded little therapeutic benefit (1). Emerging data suggest that thioredoxin-interacting protein (TXNIP) could provide a new candidate therapeutic target (2, 3), and a clear rationale for this is now provided by the work of Yoshioka et al. reported in this issue of the JCI (4).
TXNIP controls energy bioavailability by altering mitochondrial redox state and respiration
Many of the features of I-R injury are related to mitochondrial dysfunction manifest by the uncoupling of oxidation-phosphorylation (OXPHOS) that leads to decreased ATP production and increased ROS generation (5). Restoring cardiac energy bioavailability and homeostatic reductionoxidation (redox) signaling are therefore important in recovery from I-R. Consequently, detailed understanding of the regulation of mitochondrial homeostasis and cellular bioenergetics is key to designing therapeutic approaches to improve cardiac function after I-R. It has recently become clear that TXNIP plays a critical role in regulating mitochondrial homeostasis and cellular bioenergetics (6) (7) (8) . TXNIP is the endogenous inhibitor of the two isoforms of thioredoxin, cytosolic thioredoxin (TRX1) and mitochondrial thioredoxin (TRX2), which are key regulators of cellular redox state insert (9) . Because TXNIP inhibits TRX2 in the mitochondria, and mitochondrial function is critical to recovery from I-R injury, it is logical to believe that decreasing TXNIP expression should improve mitochondrial function and recovery from I-R injury.
This hypothesis is supported by recent data showing that TXNIP has redoxdependent effects on mitochondria (Figure 1 and refs. 7, 8 ). One set of data indicates that TXNIP-deficient mice exhibit increased glycolysis and Akt signaling associated with impaired mitochondrial fuel oxidation and loss of phosphatase and tensin homolog (PTEN) activity (7). Mechanistically, the PTEN active site contains two critical cysteine residues (Cys-71 and Cys-124) that must be in the reduced form for proper catalytic activity. Alterations in the redox state of those residues are linked to the mitochondrial respiration rate and to the ability of TRX to interact with PTEN, which is regulated by TXNIP. The second set of data indicates that TXNIP translocates from the nucleus to the mitochondria in response to changes in cellular redox state and targets TRX2 (8) . As a result, TRX2 activity decreases, which induces dissociation of TRX2 from apoptosis signal regulating kinase 1 (ASK1) and release of its inhibitory effect. ASK1 dissociation from TRX2 leads to increased ASK1 activity and subsequent induction of mitochondria-mediated apoptotic signaling, including cytochrome c release and caspase-3 activation. An exciting and surprising insight into TXNIP control of mitochondria function Yoshioka et al. definitively prove the hypothesis that decreasing TXNIP expression improves recovery after I-R injury (4). Using mice in which Txnip was deleted in every cell, as well as those in which the gene was deleted in a cardiac-specific manner, the authors showed that after I-R injury, left ventricular function was improved in TXNIP-deficient versus wild-type mice. Unexpectedly, the improvement in left ventricular function was accompanied by a decrease, not an increase, in mitochondrial respiratory function. Yoshioka et al. went on to determine the mechanism underlying the beneficial effect of TXNIP deletion by several approaches. First, they performed bioinformatics analyses of the transcriptome and proteome in TXNIPdeficient mouse hearts to identify pathways altered by Txnip deletion. The mRNA expression approach revealed 390 genes regulated by TXNIP, of which 306 were downregulated. In addition, they showed an altered gene expression that primarily led to decreased expression of proteins important for energy metabolism. More specifically, proteins that are involved in OXPHOS or fatty acid/ carbohydrate metabolism associated with metabolic pathways in the mitochondria. The proteomics approach revealed 21 proteins that were differentially regulated, of which 13 had described cellular functions, and all were decreased in TXNIP-deficient mouse hearts. Among the 13 proteins, 12 were related to mitochondrial metabolism, which supports the notion that TXNIP is a key regulator of mitochondrial function in the heart. Second, Yoshioka et al. used skinned cardiac myocyte fibers and isolated mitochondria to show that deletion of Txnip in mice was associated with reduced mitochondrial function. This was not due to a loss of respiratory complexes, but resulted from a functional loss of ADP-stimulated respiration. There was also no change in mitochondrial permeability transition pore opening. Third, the authors showed that, surprisingly, there was no change in the number of mitochondria or in their structure. However, electron microscopy showed large perimitochondrial lipid droplets and matrix granules in the mitochondria of TXNIP-deficient hearts, suggestive of altered fatty acid and lipid metabolism. Fourth, they measured the activity of TRX1 and TRX2. Although there was no change in TRX1 activity, there was a substantial increase in TRX2 activity and a decrease in ROS generation in TXNIP-deficient mice that was apparent after I-R injury. Fifth, they determined cellular ATP content after I-R, which was 2-fold greater in TXNIP-KO hearts. This was due to a shift from aerobic to anaerobic metabolism, as shown by blocking glycolysis. Finally, the authors studied the role of the pyruvate dehydrogenase complex, which regulates glycolytic flux relative to mitochondrial respiration. They found that TXNIP binds to pyruvate dehydrogenase (PDH), specifically pyruvate dehydrogenase E1 component, subunit α (Figure 1 ). In TXNIP-deficient hearts, PDH activity was inhibited, and there was a shift in the use of glycolytically derived pyruvate away from its metabolism in mitochondria toward cytosolic lactate production and ATP generation.
In summary, Yoshioka et al. demonstrated that TXNIP acts as a metabolic switch to enhance ATP production by anaerobic pathways via its ability to inhibit mitochondrial respiration (4). Moreover, TXNIP was shown to mediate this function by both decreasing expression of mitochondrial OXPHOS proteins and by redirecting pyruvate away from mitochondria.
Exciting findings, further complexity in TXNIP biology
A complexity in interpreting the results of Yoshioka et al. is the fact that although TXNIP regulates mitochondrial respira- 
Figure 1
TXNIP regulates mitochondrial function via several pathways. First, TXNIP regulates fuel use in the mitochondria via inhibition of TRX2 and alteration of PTEN-Akt signaling. Second, TXNIP translocates to the mitochondria in response to changes in cellular redox state, resulting in inhibition of TRX2 and subsequent activation of ASK1 that leads to opening of the mitochondrial permeability transition pore. Third, as shown by Yoshioka et al., TXNIP interacts with PDH and acts as a metabolic switch between aerobic and anaerobic metabolism (4) . Last, TXNIP expression is closely regulated by the MondoA:MLX transcription factor, which is activated by glucose uptake, glycolytic intermediates generated by the mitochondria, and lactate. tion and energy production, TXNIP expression itself is regulated by glucose and glycolytic intermediates (6) . It is therefore possible that drugs that inhibit TXNIP expression or function may paradoxically stimulate pathways that increase TXNIP expression (Figure 1 ). In addition, TXNIP appears to have many functions in subcellular compartments besides mitochondria (Table 1 and reviewed in ref. 10) . First, in the nucleus, TXNIP acts as a growth suppressor via interaction and inhibition of Jun activation domain-binding protein 1 (JAB1) (11) . TXNIP has also been shown to mediate TRX1 translocation into the nucleus, resulting in the regulation of cardiac hypertrophy (12) . Second, TXNIP shuttles HIF1α from the nucleus to the cytosol, targeting it for proteasomal degradation (13) . Third, the TXNIP-TRX1 complex has previously been shown to translocate to the plasma membrane to promote activation of VEGFR2, resulting in endothelial cell survival and migration (14) . Finally, TXNIP can facilitate the transport of proteins to the plasma membrane, an effect that may be important for cell signaling (15) . These findings suggest multiple regulatory mechanisms for both TXNIP expression and TXNIP subcellular location, which together determine the overall function of TXNIP.
Starting to unfold the complexity: TXNIP as an arrestin protein Another complexity in TXNIP biology is that it belongs to a class of proteins termed the α-arrestins. The function of α-arrestins is not well known, but it is clear that they participate in multiple protein interactions (16) . The function of TXNIP as an arrestin is best exemplified by recent data demonstrating that the TXNIP-TRX1/2 complex is itself a signaling mediator (14, 17 
Summary
There is increasing appreciation of the importance of TXNIP in the cardiovascular system, since it has the ability to integrate signals related to changes in redox state, inflammation, metabolism, and biomechanical forces (2, 3, (18) (19) (20) . Furthermore, because TXNIP expression is highly regulated by multiple stimuli and has a very short half-life, it should be an easy target for drugs that limit its expression. Alternatively, drugs that prevent its interaction with key proteins, such as TRX1, TRX2, PDH, and nuclear transcription factors, should have powerful effects in a variety of diseases. The work by Yoshioka et al. (4) provides a further rationale to focus on TXNIP as a therapeutic target for I-R injury.
